Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.

Area of Science:

• Molecular Biology
• Clinical Diagnostics
• Hematology

Background:

• Advances in molecular biology enable sensitive detection of cellular components in clinical settings.
• Neoplastic hematologic cells release tumor-specific DNA, RNA, and proteins into plasma.
• High turnover of cancer cells enriches plasma, facilitating detection.

Purpose of the Study:

• To review recently developed plasma-based assays for hematologic diseases.
• To highlight the potential of these assays to alter the diagnostic and monitoring paradigm.
• To compare the efficacy of plasma testing versus bone marrow biopsy.

Main Methods:

• Review of recent literature on plasma-based molecular assays.
• Analysis of data comparing plasma detection sensitivity with bone marrow analysis.
• Discussion of the principles behind plasma enrichment with tumor-specific markers.

Main Results:

• Plasma-based assays show promise in reducing the need for bone marrow biopsy.
• These assays allow for more frequent and accurate monitoring of disease status.
• Plasma testing can detect aggressive subclones and quantify malignant cell load more effectively.
• In some cases, plasma offers superior sensitivity to bone marrow cells.
• Plasma testing aids in distinguishing homozygous from hemizygous abnormalities due to reduced dilution effects.

Conclusions:

• Plasma-based molecular testing represents a significant advancement in diagnosing and managing hematologic malignancies.
• These assays offer a more sensitive, quantitative, and less invasive alternative to bone marrow biopsy.
• Current data suggest plasma is superior to cellular analysis for detecting molecular abnormalities in hematologic diseases.